Immunomodulated Nucleic Acid Particles for Low-Inflammation Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nucleic acid therapies face challenges with nucleic acid stability, degradation, and inflammatory responses upon administration, limiting their effectiveness and safety.
Innovation Solution
Incorporation of immunomodulatory compounds, such as TLR inhibitors and inflammasome inhibitors, into nucleic acid particles to enhance stability and reduce inflammatory responses, thereby improving protein expression and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acid particles comprising cationic lipids (LNPs) are used for delivery, then delivery effectiveness is improved, but inflammatory response increases
Solution Approach 1:
The patent introduces immunomodulatory compounds as intermediary substances within the LNP structure. These compounds act as mediators that modulate the immune system's response to the cationic lipids, reducing inflammatory reactions while preserving the delivery function. The immunomodulators are incorporated into the particle formulation to actively manage the harmful immune response.
Solution Approach 2:
The patent creates a composite nucleic acid particle system that combines cationic lipids with immunomodulatory compounds. This composite structure integrates the delivery capabilities of LNPs with the immune-modulating properties of the additional compounds, allowing simultaneous achievement of effective delivery and reduced inflammation.
2Productivity
If nucleic acid particles are administered to target tissue, then protein expression is achieved, but nucleic acid degradation occurs
Solution Approach 1:
The patent applies preliminary protective action by incorporating stabilizing components into the nucleic acid particle formulation before administration. These pre-integrated protective elements shield the nucleic acid from degradation during circulation and delivery, ensuring it reaches the target tissue intact and functional for protein expression.
Data Source
AI summary
The present disclosure provides nucleic acid particles comprising an immunomodulator, RNA, and a cationic lipid or a cationic polymer, wherein nucleic acid particles described herein reduce inflammatory response and/or increase protein or antigen expression associated with previous formulations.